Community-acquired pneumonia in ambulatory patients: Relative importance of atypical pathogens

International Journal of Antimicrobial Agents

Volumn 18, Issue SUPPL.1, 2001, Pages 57-61

  Honeybourne, D ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Atypical pneumonia; Chlamydia pneumoniae; Community acquired pneumonia; Epidemiology; Legionella species; Mycoplasma pneumoniae

Indexed keywords

AMBULATORY CARE; BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; DISEASE TRANSMISSION; GEOGRAPHY; HOSPITALIZATION; HUMAN; MICROBIOLOGY; PATIENT CARE; REVIEW;

AMBULATORY CARE; COMMUNITY-ACQUIRED INFECTIONS; GEOGRAPHY; HOSPITALIZATION; HUMANS; PATIENT CARE MANAGEMENT; PNEUMONIA, BACTERIAL;

EID: 0001777630     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0924-8579(01)00398-3     Document Type: Article

References (36)

1. Mulazimoglu L. Treatment of community-acquired pneumonia in hospitalised patients. Int J Antimicrob Agents 2000;18(Suppl. 1):63-70.
2. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987;i:671-4.
3. The British Thoracic Society and the Public Health Laboratory Service. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. Q J Med 1987;62:195-220.
4. Macfarlane JT, Finch RG, Ward MJ, Macrae AD. Hospital study of adult community-acquired pneumonia. Lancet 1982;ii:255-8.
5. McNabb WR, Shanson DC, Williams TD, Lant AF. Adult community-acquired pneumonia in central London. J R Soc Med 1984;77:550-5.
6. White RJ, Blainey AD, Harrison KJ, Clarke SK. Causes of pneumonia presenting to a district general hospital. Thorax 1981;36:566-70.
7. Woodhead MA, Macfarlane JT, Rodgers FG, Laverick A, Pilkington R, Macrae AD. Aetiology and outcome of severe community-acquired pneumonia. J Infect 1985;10:204-10.
8. The British Thoracic Society Research Committee and The Public Health Laboratory Service. The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. Respir Med 1992;86:7-13.
9. Hirani NA, Macfarlane JT. Impact of management guidelines on the outcome of severe community acquired pneumonia. Thorax 1997;52:17-21.
10. Alkhayer M, Jenkins PF, Harrison BD. The outcome of community acquired pneumonia treated on the intensive care unit. Respir Med 1990;84:13-6.
11. Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydia psittaci strain called TWAR from acute respiratory infections. N Engl J Med 1986;315:161-8.
12. Marrie TJ, Peeling PW, Fine MJ, Singer DE, Coley CM, Kapoor WN. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996;101:508-15.
13. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 1990;69:307-16.
14. Almirall J, Morato I, Riera F, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 1993;6:14-8.
15. Lim WS, Macfarlane JT, Boswell TCJ, Harrison TG, Leinonen M, Saikku P. SCAPA-study of community-acquired pneumonia aetiology in the UK: interim results. Eur Respir J 2000;16(Suppl.):551S-2S.
16. Melbye H, Berdal BP, Straume B, Russell H, Vorland L, Thacker WL. Pneumonia - a clinical or radiographic diagnosis? Etiology and clinical features of lower respiratory tract infection in adults in general practice. Scand J Infect Dis 1992;24:647-55.
17. Berntsson E, Lagergard T, Strannegard O, Trollfors B. Etiology of community-acquired pneumonia in out-patients. Eur J Clin Microbiol 1986;5:446-7.
18. Blanquer J, Blanquer R, Borras R, et al. Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study. Thorax 1991;46:508-11.
19. Michetti G, Pugliese C, Bamberga M, et al. Community-acquired pneumonia: is there difference in aetiology between hospitalised and out-patients? Minerva Med 1995;86:341-51.
20. Cook PJ, Honeybourne D. Chlamydia pneumoniae. J Antimicrob Chemother 1994;34:859-73.
21. Marrie TJ. Coxiella burnetii (Q fever) pneumonia. Clin Infect Dis 1995;21(Suppl. 3):5253-64.
22. Sobradillo V, Ansola P, Baranda F, Corral C. Q fever pneumonia: a review of 164 community-acquired cases in the Basque country. Eur Respir J 1989;2:263-6.
23. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26:811-38.
24. Foy HM, Kenny GE, Cooney MK, Allen ID. Long term epidemiology of infections with Mycoplasma pneumoniae. J Infect Dis 1979;139:681-7.
25. Hers JF, Masurel N. Infections with Mycoplasma pneumoniae in civilians in The Netherlands. Ann NY Acad Sci 1967;143:447-60.
26. Marston BJ, Lipman HB, Breiman RF. Surveillance for Legionnaires' disease. Risk factors for morbidity and mortality. Arch Intern Med 1994;154:2417-22.
27. Tobiansky L, Drath A, Dubery B, Koornhof HJ. Seasonality of Legionella isolates from environmental sources. Isr J Med Sci 1986;22:640-3.
28. Fallon RJ. Legionella infections in Scotland. J Hyg (London) 1982;89:439-44.
29. Dupuis G, Petite J, Peter O, Voilloz M. An important outbreak of human Q fever in a Swiss alpine valley. Int J Epidemiol 1987;16:282-7.
30. Chanock RM. Mycoplasma infections of man. N Engl J Med 1965;273:1199-206.
31. Grayston JT, Campbell LA, Kuo CC, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990;161:618-25.
32. Tan JS. Role of 'atypical' pneumonia pathogens in respiratory tract infections. Can Respir J 1999;6(Suppl. A):15A-9A.
33. Ruiz-Gonzalez A, Falguera M, Vives M, Nogues A, Porcel JM, Rubio-Caballero M. Community-acquired pneumonia: development of a bedside predictive model and scoring system to identify the aetiology. Respir Med 2000;94:505-10.
34. Garau J. The impact of macrolide resistance. Int J Antimicrob Agents 2001;18(Suppl. 1):33-8.
35. Pontani D, Washton H, Boucillon S, Johnson J. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. Eur J Clin Microbiol Infect Dis 1998;17:413-9.
36. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399-408.